



SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

13th May 2024

To,
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

Scrip Code: 531569

ISIN: INE860D01013

Subject: Press Release

We enclose herewith a Press Release issued by the Company on Audited Financial Results for the quarter and year ended March 31, 2024.

Please take same on your record.

Thanking You,

Yours faithfully,
For Sanjivani Paranteral Ltd.

Pritesh Jain
Chief Financial Officer

Encl: As Above

Press Release

Sanjivani Paranteral Limited reported a strong performance for the quarter ended 31st March 2024

Mumbai, 13th May 2024: Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Commenting on the results, Mr. Ashwani Khemka Chairman & Managing Director, Sanjivani Paranteral Ltd. said, “Looking ahead, we are excited about the opportunities that lie ahead for Sanjivani Paranteral. Our strategic investments in expansion into new geographies, and the introduction of innovative products have positioned us for continued success and sustainable growth. As we navigate the evolving healthcare landscape, we remain steadfast in our commitment. The company is on track on achieving its target for future.”

Financial Summary:

Q4 FY24:

- Revenue from operation grew 58.38% YoY to Rs. 128.64mn.
- EBITDA grew 59.9% YoY to Rs.22.10mn. Margin stood at 17.18%.
- Profit After Tax (PAT) grew 26.2% YoY to Rs. 12.58mn. PAT margin stood at 9.78%.

Segment-wise Performance:

- **Injectables:** Revenue grew 52.90% YoY to Rs. 81.1mn.
- **Oral:** Revenue grew 66.23% YoY to Rs. 42.94mn.
- **Nutraceuticals:** Revenue grew 137% YoY to Rs. 4.59mn.

Market-Wise Performance:

- Exports (incl. Exports incentives) constitutes 73% of total revenue while domestic constitutes the rest.
- Core markets of CIS (incl Russia), Middle east & Africa and Latin America, accounted for 66.85 % to Rs. 86mn.

FY24:

- Revenue from operation grew 53.31% YoY to Rs. 544.1mn.
- EBITDA grew 41.47% YoY to Rs.87.58mn. EBITDA margin stood at 16.10% (down 135bps YoY) led by lower price realization in some products.
- Profit After Tax (PAT) grew 36.65% YoY to Rs. 61.65mn. PAT margin stood at 11.33% (down 138bps YoY). Led by lower price realization in some products.

Pritesh Jain

Sanjivani Paranteral
Chief Financial Officer
pritesh.jain@sanjivani.co.in

Vijay Gyanchandani / Jill Chandrani

S-ancial Technologies
vijay@s-ancial.com / jill@s-ancial.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.